Polymeric cups for cavitation mediated delivery of oncolytic vaccinia virus

Rachel Myers, Christian Coviello, Philippe Erbs, Johann Foloppe, Cliff Rowe, James Kwan, Calum Crake, Sean Finn, Edward Jackson, Jean-Marc Balloul, Colin Story, Constantin Coussios, Robert Carlisle

Cite this article as: Rachel Myers, Christian Coviello, Philippe Erbs, Johann Foloppe, Cliff Rowe, James Kwan, Calum Crake, Sean Finn, Edward Jackson, Jean-Marc Balloul, Colin Story, Constantin Coussios, Robert Carlisle, Polymeric cups for cavitation mediated delivery of oncolytic vaccinia virus, Molecular Therapy accepted article preview online 30 June 2016; doi:10.1038/mt.2016.139

This is a PDF file of an unedited peer-reviewed manuscript that has been accepted for publication. NPG is providing this early version of the manuscript as a service to our customers. The manuscript will undergo copyediting, typesetting and a proof review before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers apply.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Received 30 December 2015; accepted 21 June 2016; Accepted article preview online 01 July 2016
Polymeric cups for cavitation mediated delivery of oncolytic vaccinia virus

Rachel Myers¹, Christian Coviello², Philippe Erbs³, Johann Foloppe³, Cliff Rowe, James Kwan¹, Calum Crake¹, Sean Finn, Edward Jackson, Jean-Marc Balloul³, Colin Story², Constantin Coussios¹, Robert Carlisle¹

¹ BUBBL, IBME, Dept Engineering Science, University of Oxford, Oxford, UK
² OxSonics Ltd, The Magdalen Centre, Robert Robinson Avenue, Oxford, UK
³ Transgene SA, Boulevard Gonthier d’Andernach, Parc d'innovation CS80166, 67405 Illkirch-Graffenstaden, France

Corresponding Author – robert.carlisle@eng.ox.ac.uk, 44 01865 617673,

Short title – Cavitation mediated vaccinia delivery
Key words – Tumor penetration, virus, cavitation, delivery

ABSTRACT

Oncolytic viruses (OV) could become the most powerful and selective cancer therapies. However, the limited transport of OV into and throughout tumors following intravenous injection means their clinical administration is often restricted to direct intratumoral dosing. Application of physical stimuli, such as focused ultrasound, offers a means of achieving enhanced mass transport. In particular, shockwaves and microstreaming resulting from the instigation of an ultrasound-induced event known as inertial cavitation can propel OV hundreds of microns. We have recently developed a polymeric cup formulation which, when delivered intravenously, provides the nuclei for instigation of sustained inertial cavitation events within tumors. Here we report that exposure of tumors to focused ultrasound after intravenous co-injection of cups and oncolytic vaccinia virus (VV), leads to substantial and significant increases in activity. When cavitation was instigated within SKOV-3 or HepG2 xenografts, reporter gene expression from VV was enhanced 1,000-fold (p<0.0001) or 10,000-fold (p<0.001), respectively. Similar increases in the number of VV genomes recovered from tumors were also observed. In survival
studies, the application of cup mediated cavitation to a VV expressing a prodrug converting enzyme provided significant (p<0.05) retardation of tumor growth. This technology could improve the clinical utility of all biological therapeutics including OV.

INTRODUCTION

Oncolytic viruses (OV) represent a powerful platform for achieving cancer therapy due to their tumor-selective self-amplification and their ability to provide expression of therapeutic proteins from within tumors [1, 2]. The next decade is likely to see a wide range of these agents continuing their progression through the clinical testing pathway both in combination with conventional anti-cancer strategies [3] and immuno-oncology approaches [4]. However, the poor delivery of OV into and throughout target tumors following systemic administration means that, to date, the majority of clinical applications are reliant on direct intra-tumoral injection, a route which is inefficient [5] and restricts the type of cancer which can be treated. In response, several methods have been employed to permit the intravenous delivery of OV, and thereby broaden their potential clinical utility. Indeed, recent studies have addressed their rapid neutralisation in the bloodstream [6-8] as well as their limited transfer from the bloodstream into tumors [9]. Notably, the activity of an OV within xenograft tumors was enhanced up to 50-fold by co-injection of SonoVue (SV), an ultrasound contrast agent, and simultaneous exposure of the tumors to focussed ultrasound [10]. Such delivery was mediated by the SV responding to ultrasound and acting as a nuclei for the instigation of inertial cavitation events, which in turn caused the microstreaming and shockwaves responsible for propelling the OV into and throughout tumors [11]. Moreover, increasing the density of the virus further enhanced this effect [12]. However, whilst SV represents a useful tool to demonstrate that ultrasound induced inertial cavitation can provide substantial enhancement of OV tumor delivery, it has poor clinical translatability due to its rapid destruction and 1-10 µm diameter. We have recently described the formulation of a novel polymeric cup (‘cups’) cavitation inducing agent which measures less than 500 nm [13]. This cups formulation provides a level of cavitation from within tumors which is
more sustained than that achieved with SV. Furthermore, whereas the micron size of SV spatially restricts its impact to the tumor vasculature, cups can self-propel through the tumor vasculature and continue to assist transport within [13][14]. We use oncolytic vaccinia virus to demonstrate that this technology can achieve dramatic increases in the efficiency of virus delivery and tumor infection which, ultimately, leads to improvements in tumor growth retardation and overall survival.

RESULTS

Impact of cup nucleated cavitation on vaccinia virus delivery

Our previous cavitation mediated delivery studies have only utilised non-enveloped viruses [10] and so tests were performed to characterise the stability of Vaccinia Virus (VV) to cavitation events (Supplementary Figure S1A). 1x10^6 plaque forming units (pfu) of a luciferase expressing vaccinia virus (VVluc) were exposed to ultrasound (US). No decrease in the ability of the VVluc to infect CT-26 cells and produce luciferase transgene resulted from the exposure of VVluc to cups mediated cavitation. The benefit of the use of cups compared to SV was demonstrated by comparing their impact on the delivery of luciferase expressing VVluc to CT26 tumors in Balb/C mice, a model in which replication is sub-optimal (Figure 1A). Mice were sacrificed and tumors analysed 48 hours after treatment and even at this early time-point a ~5-fold increase in luciferase expression was evident for SV + VVluc + US treated mice compared to the VV alone group. Although large this effect did not reach significance (in line with a previous study using Adenovirus and SV, where SV produced impressive yet variable results [9]). Notably, cups + VVluc + US provided an even greater enhancement of delivery, achieving levels of luciferase which were >45-fold greater than VV alone and >6-fold greater than achieved using SV + VVluc + US (738,450 vs 115,855 light units/g tumor, p<0.01), (Figure 1A). The administration of VVluc with inactivated cups (i-cups), cups which were formulated to be unresponsive to US, and US exposure provided no enhancement of reporter gene expression compared to the delivery of VVluc alone (light units/g tumor = 19,773 vs 22,760 p>0.05). This demonstrates that neither cups alone nor US
alone is a sufficient condition to enhance delivery of the VV. Passive acoustic mapping performed during exposure showed that in the presence of i-cups the US parameters used here were insufficient to create cavitation within the tumor. Furthermore, such mapping demonstrated the superior maintenance of cavitation signal achieved with cups vs SV. (Supplementary Figure S1B). To probe the impact of improved delivery on the ability of VV to replicate and spread over prolonged durations these experiments were extended with the use of a CD-1 nude mouse with HepG2 tumors, a model which is more amenable to supporting VV infection. In this way the two studies in Figure 1 allowed assessment of the impact of cavitation on both initial delivery (CT26 cells) and subsequent spread (HepG2 cells). Notably, 5 days after treatment mice with HepG2 tumors dosed with cups + VV + US provided more than 125-fold greater luminescent signal compared to those dosed with cups + VV alone (p<0.05) and 6-fold increase over those dosed with SV + VV + US (Figure 1B). The images of these mice (shown in Supplementary Figure S2) also serve to demonstrate the greater reproducibility of delivery achieved using cups rather than SV.

**Impact of cup nucleated cavitation on vaccinia virus infection of tumors**

Having demonstrated the advantage of the use of cups over SV, the SV group could now be excluded from further experiments. When CD1 nude mice bearing xenograft HepG2 tumors were co-injected with 2.5 mg of cups and just 1x10^5 pfu of VVluc, very low levels (~1x10^4 photons/second/cm^2) of luciferase expression were detected by IVIS imaging at 24 hours (Figure 2A). This level did not substantially increase over the subsequent 20 days, with only one mouse of four showing levels exceeding 1x10^5 photons/second/cm^2. In contrast, when the exact same procedure was performed whilst the tumor was exposed to US (see Methods for details) luciferase expression reached 3.1x10^5 photons/second/cm^2 by 24 hours and 3.5x10^8 by 10 days, this level was maintained in all these mice until sacrifice at 20 days. Mapping of the cavitation within tumors allowed real-time validation of the success of cavitation instigation and confirmed the presence of cups within tumors. QPCR of tumors rescued following sacrifice at day 20 (see Methods) confirmed the benefit of cup mediated cavitation enhanced delivery
(Figure 2B). In the tumors of mice treated with cups + VV without US, negligible levels of VV DNA were recovered. In contrast tumors from cups + VV + US treated mice contained nearly $1 \times 10^8$ VV genome copies, representing an approximate 1,000-fold increase compared to the original IV injected dose and a 10,000-fold increase compared to tumors of mice treated with cups but no US. Meanwhile VV expression in the liver remained equally negligible in the cups + VV group and the cups + VV + US group as evident from IVIS imaging (see Figure 2) and from QPCR analysis following sacrifice at day 20 (Supplementary Figure S3).

When these experiments were repeated in mice bearing SKOV-3 tumors the same pattern was observed (Supplementary Figure S4), with the production of cavitation within the tumor again correlating with 1000-fold increase in luciferase expression and genome copy number at 20 days (Supplementary Figure S4A and B).

**Impact of cup nucleated cavitation on vaccinia virus retardation of tumor growth**

HepG2 tumor growth was not affected when mice were dosed with just $1 \times 10^5$ VVluc, regardless of the delivery enhancement provided by cups and US (Supplementary Figure S5). It is hypothesised that, despite the substantial and significant increase in VVluc concentration in the tumor achieved by the cup and US treatment, the VVluc dose in the tumor is still below the efficacious concentration. Approaches to overcome this therapeutic threshold include increasing the dose of VVluc used or arming the VV with a therapeutic transgene rather than the reporter gene luciferase. The first of these options was explored in Figure 3, where a dose of $10^6$ VVluc was used in combination with cups and US.

Retardation of HepG2 and SKOV-3 tumor growth was observed in mice treated with cups + VV + US compared to controls which received cups + VV but no US. In 4 out of 4 SKOV-3 tumors and in 3 out of 4 HepG2 tumors growth was controlled when cups + VV + US was used, whereas all but one tumor treated with just cups + VV showed continued growth. Notably the one tumor which did not respond to treatment in the cups + VV + US treated group showed the lowest cavitation response as detected by PAM, demonstrating the utility of such monitoring in identifying potential treatment failures. Analysis
of mean data from these experiments demonstrated that although a significant (p<0.05) impact on tumor growth in mice bearing SKOV-3 tumors was achieved with cups + VV + US, in mice bearing HepG2 tumors such significance was not reached (as a result of the mouse with ‘failed’ levels of cavitation). This demonstrates the potential utility of this approach in enhancing treatment and the value of cavitation monitoring, but also emphasises the need to test VV armed with therapeutic transgene rather than a reporter transgene.

Recent studies have demonstrated that the bloodstream neutralisation of VV will rapidly reduce the active circulating dose of VV vectors [7]. In the face of such a limitation, it is essential that that the small proportion of the dose that does remain bio-available is delivered into the tumor as effectively as possible and then has the maximal anti-tumor effect achievable.

Enhancement of oncolytic effect can be provided by the expression of a range of proteins which may enhance spread [15, 16], instigate an immune response [17], inhibit vascularisation [18] or convert non-toxic pro-drugs in to active metabolites [19]. This prodrug converting enzyme approach has recently been further explored with the development of a vaccinia virus (VVTK-RR-/FCU1) which encodes an enzyme which converts 5-Fluorocytosine (5-FC) into the anti-metabolite chemotherapeutic 5-Fluorurocil (5-FU) [20, 21]. In previous studies when mice bearing xenograft tumors were dosed twice IV with VVTK-RR-/FCU1 at 1x10⁶ copies and 5-FC dosing commenced daily at 7 days, substantial tumor retardation was shown [21]. The work reported in Figure 2 using VVluc raised the possibility that an anti-tumor effect could even be achieved with VVTK-RR-/FCU1 at a dose of just 1x10⁵ copies, provided cups and US were used to enhance delivery. Figure 4A demonstrates that compared to all other control groups the use of cups + VVTK-RR-/FCU1 + US + 5-FC showed enhanced retardation of tumor growth (p<0.05). Pictures of representative tumors taken at day 11 exemplify the dramatic impact of cavitation-mediated enhanced VV delivery on tumor size (Figure 4B).
Survival analysis demonstrated that whilst 50% of all other groups were sacrificed before day 33 or sooner due to tumor size reaching the limit permitted under the licence governing these studies, 50% of mice treated with cups + VVTK-RR-/FCU1 + US + 5-FC were not sacrificed until day 39 (see Supplementary table S1).

It is notable that an impact on tumor retardation was evident in this experiment even prior to the commencement of 5-FC delivery. This does not directly align with the findings of Figure 3 which demonstrates that although growth is slower than in controls at these early time-points with VVluc + cups + US, the effect is not as marked as that achieved with 10-fold lower titre of VVTK-RR-/FCU1 + cups + US in figure 4A. It is hypothesised that the discrepancy in level of anti-tumor effect achieved with VVluc compared to VVTK-RR-/FCU1 may be due to differences in oncolytic efficacy of these two viruses in this HepG2 cell line.

**DISCUSSION**

Instigation of ultrasound mediated cavitation offers a non-invasive, safe, targetable and monitorable means of delivering and activating drugs within tumors [13][10, 22]. The inefficient delivery of OVs into and throughout tumors following their IV injection is one of the few remaining barriers to their widespread clinical translation [23]. Interactions with complement, blood cells and the reticuloendothelial system very rapidly reduce the active circulating OV dose [6, 7], whilst the high pressure and dense extracellular matrix within tumors restricts OV infection to the perivascular space and prevents optimal spread beyond initial infection foci [10, 24]. Hence, although OVs have now been approved for use in humans, this is in the context of intratumoral injection [25, 26], a route which restricts potential efficacy [5] and the range of applicable indications.
Vaccinia virus (VV) is a popular candidate for development as an OV due to its strong safety track record, well defined genome and large coding capacity. It is clear from clinical trials utilising direct intratumoral delivery that the survival duration of patients is related to the VV dose delivered into their tumors [27]. However, when injected systemically VV is prone to the bloodstream clearance mechanisms outlined above. This means that despite early promise [28], IV dosing of VV has not yet demonstrated marked clinical efficacy. Indeed, although a ‘breakthrough’ dose of VV of $1.5 \times 10^7$ pfu/kg has been identified, simply increasing the dose to enhance efficacy is not feasible in terms of cost or safety [7]. It is clear that, although the VV dose remaining in the circulation following IV delivery may represent only a small percentage of that injected, it is still active and infective [27, 29, 30]. Mechanisms of ensuring improved delivery of this active circulating dose into and throughout the tumor may offer a means by which clinical efficacy may be more readily achieved. Whilst arming the vector with therapeutically powerful transgenes will ensure any VV which does successfully deposit, has as much anti-tumor effect as possible. We have previously demonstrated that technologies which instigate, control and measure inertial cavitation can provide a powerful and targeted method to drive drugs, such as antibodies and oncolytic adenoviruses, deep into tumors following either intratumoral or intravenous delivery [9] [13] [31]. Here we demonstrate this technology is well suited to delivery of oncolytic VV, with 1,000 to 10,000-fold increases in the infection of human cancer cell line xenografts in murine models, achieved only when VV is injected in combination with our proprietary cups formulation and ultrasound is focussed on the tumor. Furthermore, use of this approach to deliver an oncolytic VV expressing an enzyme for the conversion of a prodrug into a cytotoxic metabolite adds further anti-cancer potency [20][32]. Refined dosing with the prodrug 5-fluorocytosine (5-FC), which is converted into the active cytotoxic metabolite 5-fluorouridine (5-FU), allows inhibition of cancer cell division without impacting too detrimentally on the replication of the VV [32]. Hence, the enhanced delivery of a more effective armed VV, resulted in significant (p<0.05) retardation of tumor growth following dosing with a single IV injection of just 100,000 copies of VVTK-RR/-FCU1. This is substantially below levels
of VV vectors used in previous work where doses of $1 \times 10^8$ [32] or 2 doses of $1 \times 10^6$ [21] have been required to show efficacy.

Although this is an encouraging first demonstration of the combination of ultrasound technology and VV and an important step forward, it is clear that the anti-tumor efficacy does not yet match the level of VV delivery enhancement achieved. It is possible that the oncolytic virus ‘infection void’ problem characterised by Miller et al [23] is still an important factor despite improved initial delivery. Experiments to investigate multiple cup and ultrasound treatment post-VV dosing to enhance spread from existing infection foci is an approach which will be studied in the further development of this strategy.

We describe a clinically translatable technology, which does not require VV reformulation or surgically invasive procedures, but can enhance delivery and replication of the VV to such an extent that 10,000-fold enhancements of transgene expression can be achieved and therapeutic benefit can be detected following a single intravenous dose of just 100,000 copies. Recent studies have emphasised the challenge faced in achieving systemic delivery of vaccinia vectors and revealed interesting approaches to extend bloodstream circulation [7]. The technology described here offers a targetable, safe, non-invasive means of ensuring that the active dose remaining in the circulation has the best chance possible of achieving anti-tumor efficacy.

**MATERIALS AND METHODS**

**Vaccinia Viruses** Attenuated recombinant vaccinia viruses were derived from the Copenhagen strain and were deleted in the thymidine kinase and ribonucleotide reductase genes. VVluc and VVTK-RR-/FCU1 expressed *Renilla* luciferase and FCU1, respectively. Viruses were propagated and titrated in chicken embryo fibroblasts as previously described in [21].
Cell lines. CT-26, HepG2 and SKOV-3 were obtained from ECACC and maintained according to their guidelines. For in vitro validation of VVluc activity, CT-26 cells at 10,000 cells/well in 96 well plates were exposed to 1 pfu VV per cell. VV had been exposed to cups + US or not. Cells were assayed for luciferase expression at 24 hours using Promega luciferase assay kit and a BMG multiwall plate reader. A BCA assay was used to assess and standardize luciferase levels to protein concentration per well as described in [33].

Cups manufacture. Cups manufacture was as described in [13]. Following air drying to entrap air as nuclei for cavitation induction, cups were resuspended in sterile filtered 5 % glucose solution to a concentration of 25 mg/mL and stored in a sterile rubber stoppered glass vial at room temperature. Inactivated cups (i-cups) were not air dried before the resuspension in 5% glucose, but still matched the size, polydispersity and surface charge of active air dried cups.

Ultrasound equipment and parameters. US set-up and exposure parameters were as described in [10] except that the system utilizes a linear array diagnostic ultrasound probe (instead of a single-element passive cavitation detector) and ultrasound generation/reception platform for conducting real-time B-mode imaging, therapeutic ultrasound transmit and real-time treatment monitoring by passive acoustic mapping (PAM).

In vivo studies. UK Home Office guidelines and the UKCCCR Guidelines for the Welfare of Animals in Experimental Neoplasia were followed. CT-26 cells (100 µL containing 2x10^5) were implanted into the flanks of BALB/c nude mice using a 27 gauge needle. HepG2 or SKOV-3 cells (100 µL containing 5x10^6) were implanted in a 1:1 mix of matrigel into the flanks of CD1 nude mice using a 27 gauge needle. When CT-26 tumors had reached 200-500 mm^3 or HepG2 and SKOV-3 tumors had reached 40-100 mm^3, mice were randomised into treatment groups and treated according to a protocol whereby the focus of a 0.5 MHz transducer was aligned onto the tumor using a B-mode image captured using a L11-4 linear array probe. Tumors were exposed to US (1.5 MPa peak negative focal pressure, 500 kHz driving frequency, 0.5 Hz pulse repetition frequency and 5% duty cycle) and, provided no cavitation...
signal from within the tumor was detected, 50 µL of VV or cups + VV (final concentration of VV as stated in figure legends, final concentration of cups = 25 mg/mL) was injected via a cannula into the tail vein 10 seconds later. A dose of 25mg/mL was used as a result of studies that demonstrated that this level gave the highest and most reliable level of cavitation (Supplementary Figure S6). This dose did not induce toxicity in these or previous studies [13] and increased the likelihood of VV and cup co-localisation within tumor vasculature. At two minutes the focus of the US was moved to a different point within the tumor and at 4 minutes a further injection of 50 µL of cups + VV was administered. Over 10 minutes US exposure continued with further movement of the focus within the tumor at 6 and 8 minutes. Passive acoustic mapping was as described in [34]. 5-FC dosing was performed by daily sub-cutaneous injection of 100 µL of a 12.5 mg/mL solution 7 days after IV treatment. CT-26 studies were performed as described for HepG2 studies but mice were sacrificed, tumors lysed and luciferase expression measured 48 hours after treatment.

**Tracking of delivery and therapy.** Delivery was assessed by IVIS imaging as described in [10]. Replication of the VV was assessed by performing QPCR for VV genomes at 20 days after treatment. Tumors and organs were homogenised using a mechanical disruptor and DNA isolated as in [9]. Primer sequences. AGATCATCGTATGGAGAGTCGTAAGAT and TGACTACGTTTTATGAGAGTCGCAAGAT and probe sequence [6FAM]ATCAAAATACAGACGTGGTCAAGGAC[AM][TAM] (Sigma) were used at 100 µM and 10 µM respectively with a qPCR Bio Probe mastermix with Rox (pcrbio) reference standard according to the manufacturer’s instructions. A standard curve of known VV concentrations spiked into tumor or organ lysates and DNA extracted was run to quantify the number of VV genome copies. Tumor growth was tracked using caliper measurements and the equation h x w x l/2.
ACKNOWLEDGEMENTS

Research was supported by RCUK (Digital Economy Programme grant number EP/G036861/1 Oxford Centre for Doctoral Training in Healthcare Innovation) (R.M.), the Engineering and Physical Sciences Research Council (EPSRC) under Programme Grant EP/L024012/1 (OxCD3: Oxford Centre for Drug Delivery Devices) (RC and CCC), by an EPSRC Challenging Engineering award (EP/F011547/1) (CCC). Data is deposited and available at http://ora.ox.ac.uk/. Conflict of interest – Robert Carlisle, Constantin Coussios, Colin Story and Christian Coviello are founders and shareholders in OxSonic Ltd which holds IP relating to the polymeric cups and ultrasound technology used in these experiments.
REFERENCES

1. Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol 2015.

2. Cripe TP, Ngo MC, Geller JJ, et al. Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients. Mol Ther 2015;23(3):602-8.

3. Galanis E, Atherton PJ, Maurer MJ, et al. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. Cancer Res 2015;75(1):22-30.

4. Breitbach CJ, Parato K, Burke J, et al. Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic. Curr Opin Virol 2015;13:49-54.

5. Bazan-Peregrino M, Carlisle RC, Purdie L, et al. Factors influencing retention of adenovirus within tumours following direct intratumoral injection. Gene Ther 2008;15(9):688-94.

6. Carlisle RC, Di Y, Cerny AM, et al. Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood 2009;113(9):1909-18.

7. Evgin L, Acuna SA, Tanese de Souza C, et al. Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques. Mol Ther 2015;23(6):1066-76.

8. Muik A, Stubbert LJ, Jahedi RZ, et al. Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency. Cancer Res 2014;74(13):3567-78.

9. Bazan-Peregrino M, Rifai B, Carlisle RC, et al. Cavitnation-enhanced delivery of a replicating oncolytic adenovirus to tumors using focused ultrasound. J Control Release 2013;169(1-2):40-7.

10. Carlisle R, Choi J, Bazan-Peregrino M, et al. Enhanced tumor uptake and penetration of virotherapy using polymer stealthing and focused ultrasound. J Natl Cancer Inst 2013;105(22):1701-10.

11. Mo S, Coussios CC, Seymour L, et al. Ultrasound-enhanced drug delivery for cancer. Expert Opin Drug Deliv 2012;9(12):1525-38.

12. Mo S, Carlisle R, Laga R, et al. Increasing the density of nanomedicines improves their ultrasound-mediated delivery to tumours. J Control Release 2015.

13. Kwan JJ, Myers R, Covicelli CM, et al. Ultrasound-Propelled Nanocups for Drug Delivery. Small 2015.

14. Kwan JJ, Graham S, Myers R, et al. Ultrasound-induced inertial cavitation from gas-stabilizing nanoparticles. Phys Rev E Stat Nonlin Soft Matter Phys 2015;92(2):023019.

15. Chen HH, Cawood R, El-Sherbini Y, et al. Active adenoviral vascular penetration by targeted formation of heterocellular endothelial-epithelial syncytia. Mol Ther 2011;19(1):67-75.

16. Guedan S, Rojas JJ, Gros A, et al. Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Mol Ther 2010;18(7):1275-83.

17. Engeland CE, Grossardt C, Veinalde R, et al. CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. Mol Ther 2014;22(11):1949-59.

18. Bazan-Peregrino M, Sainson RC, Carlisle RC, et al. Combining virotherapy and angiography for the treatment of breast cancer. Cancer Gene Ther 2013;20(8):461-8.

19. Dias JD, Liikanen I, Guse K, et al. Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1. Clin Cancer Res 2010;16(9):2540-9.

20. Erbs P, Findeli A, Kintz J, et al. Modified vaccinia virus Ankara as a vector for suicide gene therapy. Cancer Gene Ther 2008;15(1):18-28.

21. Foloppe J, Kintz J, Futin N, et al. Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus. Gene Ther 2008;15(20):1361-71.
22. Carlisle R, Mo S, Myers R, et al. Increased Adenovirus density for increased ultrasound-mediated delivery to tumors. In: HUMAN GENE THERAPY. 2013: Abstract 24, p. A61-A61. MARY ANN LIEBERT, INC 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA.

23. Miller AC, Russell SJ. Heterogeneous delivery is a barrier to the translational advancement of oncolytic virotherapy for treating solid tumors. Virus Adaptation & Treatment 2014;6.

24. Miller A, Suksanpaisan L, Naik S, et al. Reporter gene imaging identifies intratumoral infection voids as a critical barrier to systemic oncolytic virus efficacy. Molecular Therapy—Oncolytics 2014;1.

25. Peng Z, Yu Q, Bao L. The application of gene therapy in China. IDrugs 2008;11(5):346-50.

26. Kaufman H, Andtbacka R, Collicchio F, et al. Primary Overall Survival (OS) from OPTiM, a Randomized Phase 3 Trial of Talimogene Laherparepvec (T-VEC) versus Subcutaneous (SC) Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for the Treatment of Unresected Stage IIIB/C/IV Melanoma. In: ANNALS OF SURGICAL ONCOLOGY. 2015: Abstract 22, p. S126-S126. SPRINGER 233 SPRING ST, NEW YORK, NY 10013 USA.

27. Heo J, Reid T, Ruo L, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 2013;19(3):329-36.

28. Breitbach CJ, Burke J, Jonker D, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011;477(7362):99-102.

29. Park SH, Breitbach CJ, Lee J, et al. Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer. Molecular Therapy 2015;23(9):1532-1540.

30. Kung C-H, Kuo S-C, Chen T-L, et al. Isolation of vaccinia JX594 from pustules following therapy for hepatocellular carcinoma. BMC cancer 2015;15(1):704.

31. Choi JJ, Carlisle RC, Coviello C, et al. Non-invasive and real-time passive acoustic mapping of ultrasound-mediated drug delivery. Phys Med Biol 2014;59(17):4861-77.

32. McCart JA, Puhlmann M, Lee J, et al. Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression. Gene Ther 2000;7(14):1217-23.

33. Carlisle RC, Read ML, Wolfert MA, et al. Self-assembling poly (L-lysine)/DNA complexes capable of integrin-mediated cellular uptake and gene expression. Colloids and Surfaces B: Biointerfaces 1999;16(1):261-272.

34. Coviello C, Kozick R, Choi J, et al. Passive acoustic mapping utilizing optimal beamforming in ultrasound therapy monitoring. J Acoust Soc Am 2015;137(5):2573-85.
FIGURE LEGENDS

Figure 1. *In vivo* infectivity of vaccinia virus delivered using SonoVue (SV) or polymeric cup (‘cups’) nucleated cavitation.

A dose of $1 \times 10^5$ luciferase expressing vaccinia virus (VV) was mixed with inactive cups (i-cups), SV or cups and injected into (A) Balb/c mice bearing CT-26 tumors. The tumors were exposed to ultrasound (US) (see Methods for parameters) and 48 hours later tumors were excised, homogenised and luciferase expression quantified (see Methods). (B) CD-1 nude mice bearing HepG2 tumors. The tumors were exposed to US and 5 days later luciferase expression was assessed by IVIS imaging (see Methods). N=4, SD shown, significant differences (* = p<0.05, ** = p<0.01, ns = p>0.05) detected by ANOVA with Tukey compare all columns post test.

Figure 2. *In vivo* infectivity of vaccinia virus (VV) delivered using polymeric cup (‘cups’) nucleated cavitation to HepG2 tumours.

A dose of $1 \times 10^5$ luciferase expressing VV was mixed with cups and injected into mice and their tumors exposed to ultrasound (US) (see methods for parameters). Passive acoustic mapping confirmed the absence or presence of cavitation within the tumor. A) Luciferase expression was assessed by IVIS imaging at intervals over the next 20 days (see Methods, inset images show luciferase expression of tumours at day 10). Green line = cups + VV + US, black dashed line = cups + VV. B) VV genome copy number within the tumors of the mice was measured at sacrifice on day 20 (see methods). N=4, SD shown, significant differences (* = p<0.05, ** = p<0.01) detected by ANOVA with Bonferroni compare all columns post test.

Figure 3. Retardation of SKOV-3 or HepG2 tumor growth in mice dosed IV with $1 \times 10^6$ copies of VV.

A dose of $1 \times 10^6$ luciferase expressing VV was injected IV with cups with or without the application of US (see Methods). Tumor size was assessed by calliper measurements. Growth profile shown for each individual tumor. N= 4. Panels A and B present SKOV-3 tumors, C and D present HepG2. Panels B and D are mice treated with cups + VV + US.

Figure 4. Retardation of HepG2 tumor growth in mice dosed IV with $1 \times 10^5$ copies of VVTK-RR/FCU1 and dosed with 5-FC.

A dose of $1 \times 10^5$ VV, expressing an enzyme for the conversion of 5-fluorocytosine to 5-fluorouracil, was injected IV with or without the application of cups and US. After 7 days 5-FC dosing commenced with daily sub cutaneous injection of 100 µL of 12.5 mg/mL (black arrow). Tumor size was assessed by calliper measurements (A). N=10, standard error of the mean shown, (* = p<0.05, by ANOVA with all group comparisons and Bonferroni post test). Black arrow denotes commencement of daily dosing with 100 µL of 12.5 mg/mL 5-FC. (B) Representative mice from the study described in 4A were photographed 9 days after dosing with VV. Dramatic differences in the size and stiffness of the tumors were observed.
Figure 1

A

B

Mean light units / g of tumour

Photons / cm²/s

PBS + VV

i-cups + VV + US

SV + VV + US

cups + W + US

cups + VV

SV + VV + US

cups + VV + US

**

* ns
Figure 2

A) cups + VV  
B) cups + VV + US
Figure 3

A

SKOV-3
Tumour size (% of start)

Days post treatment

B

cups + VV + US

Tumour size (% of start)

Days post treatment

C

HeLa
Tumour size (% of start)

Days post treatment

D

HepG2
Tumour size (% of start)

Days post treatment
Figure 4

The figure shows a graph depicting tumor size (mm$^3$) over days after treatment. The x-axis represents days after treatment, ranging from 0 to 15. The y-axis represents tumor size in mm$^3$, ranging from 0 to 450. The graph compares different treatment groups:

- Glucose
- VV + Cups
- VV + Cups + 5-FC
- VV + US + 5-FC
- VV + Cups + US + 5-FC

The data points are marked with error bars, indicating variability in the measurements. The graph includes asterisks (*) to denote statistically significant differences between groups.

Below the graph, there are images showing tumor growth in different treatment groups, providing a visual representation of the data.